FDG-PET for Pharmacodynamic Assessment of the Fatty Acid Synthase Inhibitor C75 in an Experimental Model of Lung Cancer

@article{Lee2007FDGPETFP,
  title={FDG-PET for Pharmacodynamic Assessment of the Fatty Acid Synthase Inhibitor C75 in an Experimental Model of Lung Cancer},
  author={Jae Sung Lee and Hajime Orita and Kathleen Gabrielson and Sara J Alvey and Ruth L. Hagemann and Francis P. Kuhajda and Edward W. Gabrielson and Martin G. Pomper},
  journal={Pharmaceutical Research},
  year={2007},
  volume={24},
  pages={1202-1207}
}
Fatty acid synthase (FAS) is an emerging target for anticancer therapy with a variety of new FAS inhibitors being explored in preclinical models. The aim of this study was to use positron emission tomography with [18F]fluorodeoxyglucose (FDG-PET) to monitor the effects of the FAS inhibitor C75 on tumor glucose metabolism in a rodent model of human A549 lung cancer. After a baseline FDG-PET scan, C75 was administered and post-treatment scans were performed serially. FAS activity was measured in… CONTINUE READING
6 Citations
28 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 28 references

an alternative to selective estrogen receptor modulators

  • R. Lupuand, J. A. Menendez. Targeting fatty acid synthase in breast, endometrial cancer
  • Endocrinology 147:4056–4066
  • 2006

new application of an old pathway

  • F. P. Kuhajda. Fatty acid synthase, cancer
  • Cancer Res. 66:5977–5980
  • 2006

FDG uptake and PCNA , Glut1 , and Hexokinase - II expressions in cancers and inflammatory lesions of the lung

  • F. J. Chrest M. Gorospe, T. S. Kumaravel, M. K. Evans, W. F. Han, E. S. Pizer
  • Neoplasia
  • 2005

Similar Papers

Loading similar papers…